Why the Australian Pharmaceutical Industries Ltd share price is plunging

Credit: Priceline

Healthcare stock Australian Pharmaceutical Industries Ltd (ASX: API) is at the top of the S&P/ASX 200 declines today after the release of its earnings results last week revealed a flat revenue and shrinking sales in its Priceline brand.

Credit Suisse has placed a neutral rating on the stock with the broker saying the short-term outlook for the company is “challenging” and Australian Pharmaceutical Industries shares are down 4.2% at the time of writing to $1.36.

The broker believes the conversion of independent pharmacies to the Priceline model could see an increase in operating leverage but PBS reforms could prove problematic as some manufacturers choose to bypass wholesale distributors and go direct to pharmacies.

Credit Suisse has reduced its price target on the stock from $1.62 to $1.50.

In the healthcare space Sigma Healthcare Ltd  (ASX: SIG) has also signalled struggles with PBS changes with its Hepatitis C medicines with Sigma shares down at the time of writing to 73c per share.

Mayne Pharma Group Ltd (ASX: MYX) shares have recovered slightly today with a gain of 0.7% to 69c per share at the time of writing after a week of falls.

Japanese Billionaire’s Prediction Will Give You Goosebumps

When a veritable investing and entrepreneurial genius speaks, it pays to listen.

In fact, he's now preparing a $100B "war chest" to invest entirely in this "terrifying" new technology, which could spell huge profits for investors.

Click here to learn about this technology and how you can profit!

Motley Fool contributor Carin Pickworth has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.